The contrast is jarring.
On one side: bespoke cures built in months for a single child.
On the other: primetime commercials for six-figure therapies aimed at viewers who may not know they’re candidates.
Both exist in the same system.
And that system prices not at cost, but at leverage.
Insurance insulates patients from immediate sticker shock. Premiums absorb the difference. The signal becomes simple:
Why not ask?
The danger is not that Americans are uniquely fragile. It is that we have built an economy in which attention functions as a clinical input.
When enough viewers reinterpret fatigue, stiffness, distraction, or sadness through the lens of possibility, clinics feel the pressure. Some of those conversations save lives. Some accelerate overdiagnosis. Many are simply expensive.
Back in the living room, the news resumed. Sofia shifted and sighed.
I unmuted the television and listened to the next commercial break arrive. Another soft-lit couple. Another calm recital of catastrophic risks delivered over birdsong.
I wondered how many viewers would walk into appointments this week carrying a brand name they did not know last month. I wondered how many families with truly rare conditions were still fighting prior authorization while the awareness machine hummed.
We have built a healthcare system where miracles are real—and marketing is louder.
If we want the miracles to feel normal instead of luxurious, the solution is not silence. It is redesign.
Approve platforms once, not from scratch each time.
Pool risk so no insurer has an incentive to stall a cure.
Separate clinical education from revenue-dependent advertising.
Fund innovation transparently, and negotiate prices honestly.
Until then, the commercial break will continue doing clinical work.
And Sofia will keep sleeping through it.